ASX Announcements

New patent granted for Neuren's NNZ-2591 in Japan
Appendix 4C - quarterly
Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA
Neuren receives final payment from Lanstead Capital
Results of Meeting
Chairman's Address at 2019 Annual Meeting of Shareholders
Validation for NNZ-2591 neurodevelopmental disorder pipeline
NNZ-2591 positive effects in Pitt Hopkins syndrome model
NNZ-2591 positive effects in Angelman syndrome model
Appendix 4C - quarterly

1 2 3 4 5 6 7 8 9 10 ... Next